Sunlon Pharmaceutical Technology

Sunlon Pharmaceutical Technology is a Shanghai-based biotechnology company and contract research organization (CRO) specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2011, the company provides integrated medicinal chemistry, lead optimization, and process chemistry services to global pharmaceutical and biotech partners. Beyond its service business, Sunlon maintains an internal R&D pipeline focused on kinase inhibitors for the treatment of autoimmune diseases and oncology. Its lead program, SL-001, is a selective Janus kinase 3 (JAK3) inhibitor currently in the pre-clinical stage for indications such as rheumatoid arthritis. The company is headquartered in the Pujiang High-tech Park in Shanghai, China.